SCHEMBL4941551

SCHEMBL4941551

COC(=O)c1cc(S(C)(=O)=O)ccc1-c1ccccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.48
SDHB P21912 1/20 0.46
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
SLC6A9 P48067 1/20 0.42
KMT2A Q03164 3/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TSHR P16473 1/20 0.42
SCD O00767 1/20 0.41
FADS1 O60427 1/20 0.41
MITF O75030 1/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4935564 0.86 PTGS2 (0.48) PTGS2SLC6A4SLC6A3SLC6A9HPGD
SCHEMBL3875536 0.85 LMNA (0.53) PTGS2SLC6A9HSD17B10ALDH1A1SCD
SCHEMBL4939310 0.84 LMNA (0.49) PTGS2SDHBSLC6A4SLC6A3KMT2A
SCHEMBL4941617 0.84 PTGS2 (0.48) PTGS2SDHBKMT2AHPGDHSD17B10
SCHEMBL3874637 0.82 PTGS2 (0.65) PTGS2SDHBSLC6A4SLC6A3SLC6A9
SCHEMBL2642360 0.81 TSHR (0.58) PTGS2HPGDHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL12192433 0.80 ALDH1A1 (0.51) SLC6A4SLC6A3KMT2AHPGDHSD17B10
SCHEMBL30949650 0.80 CYP46A1 (0.55) SLC6A4SLC6A3KMT2AHPGDHSD17B10
SCHEMBL4938374 0.80 SLC6A4 (0.58) PTGS2SLC6A4SLC6A3SLC6A9NPC1
SCHEMBL30876354 0.79 SLC6A3 (0.65) SLC6A4SLC6A3KMT2AHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
EP-1858869-A1 ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors SLC1A1, SLC6A7, SLC1A2 PTGS2 2558/4885SDHB 4076/4885SLC6A4 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.